Universal Beteiligungs und Servicegesellschaft mbH Has $11.01 Million Holdings in Medpace Holdings, Inc. $MEDP

Universal Beteiligungs und Servicegesellschaft mbH cut its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 13.2% in the third quarter, Holdings Channel reports. The firm owned 21,416 shares of the company’s stock after selling 3,271 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Medpace were worth $11,011,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Quent Capital LLC acquired a new position in Medpace in the third quarter worth approximately $25,000. Geneos Wealth Management Inc. grew its position in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares in the last quarter. Employees Retirement System of Texas acquired a new position in shares of Medpace during the 2nd quarter worth $36,000. Root Financial Partners LLC bought a new position in shares of Medpace during the 3rd quarter valued at $38,000. Finally, IFP Advisors Inc lifted its stake in shares of Medpace by 223.3% in the 2nd quarter. IFP Advisors Inc now owns 194 shares of the company’s stock valued at $61,000 after purchasing an additional 134 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $588.05 on Friday. The stock’s 50-day moving average is $583.65 and its 200-day moving average is $521.26. The company has a market cap of $16.57 billion, a P/E ratio of 41.12, a P/E/G ratio of 1.97 and a beta of 1.43. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $628.92.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.36. The firm had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The firm’s revenue for the quarter was up 23.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.01 EPS. As a group, equities analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insiders Place Their Bets

In other news, President Jesse J. Geiger sold 21,503 shares of the stock in a transaction that occurred on Wednesday, November 5th. The stock was sold at an average price of $595.66, for a total value of $12,808,476.98. Following the completion of the sale, the president directly owned 15,000 shares of the company’s stock, valued at approximately $8,934,900. This represents a 58.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Susan E. Burwig sold 20,000 shares of the firm’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the completion of the sale, the vice president owned 27,500 shares in the company, valued at approximately $16,751,625. The trade was a 42.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 387,925 shares of company stock valued at $233,386,647 in the last three months. Company insiders own 20.30% of the company’s stock.

Analysts Set New Price Targets

MEDP has been the topic of several analyst reports. Wall Street Zen raised shares of Medpace from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a research note on Friday, October 31st. Zacks Research downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Robert W. Baird set a $613.00 target price on Medpace in a report on Friday, October 24th. Finally, Barclays upped their target price on Medpace from $485.00 to $525.00 and gave the stock an “underweight” rating in a research report on Monday, December 15th. Two analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, Medpace has an average rating of “Reduce” and a consensus target price of $491.27.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.